home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 06/29/20

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - VistaGen Therapeutics reports FY results

VistaGen Therapeutics (NASDAQ: VTGN ): FY GAAP EPS of -$0.50. More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

VTGN - VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update

SOUTH SAN FRANCISCO, Calif. , June 29, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet nee...

VTGN - Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal

Deals and Financings VistaGen (VTGN) of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement. VistaGen's PH94B is a rapid-onset neurosteroid drug candidate for mul...

VTGN - VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

SOUTH SAN FRANCISCO, Calif. and SHANGHAI , June 25, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with...
VTGN - VistaGen teams up with Nuformix in central nervous system therapeutics

VistaGen Therapeutics ( VTGN ) will collaborate with Nuformix plc to develop novel cocrystal-based formulations of VTGN central nervous system (CNS) candidates. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, Read more ...

VTGN - VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions

SOUTH SAN FRANCISCO, Calif. , May 27, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet need...

VTGN - VistaGen submits guidelines for Phase 2A study of PH94B

VistaGen Therapeutics ( OTC:VTGN ) has submitted its proposed protocol to the FDA for a Phase 2A study of PH94B, its investigational anti-anxiety drug, for treatment of adjustment disorder with anxiety (AjDA) related to the COVID-19. More news on: VistaGen Therapeutics, Inc., H...
VTGN - VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)

SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain central nervous system (CNS) diseases and disorders with hi...

VTGN - VistaGen Therapeutics files for 13.1M common shares

VistaGen Therapeutics ( OTC:VTGN ) has filed a prospectus  for a 13.1M common shares from stockholders. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, , Read more ...

VTGN - VistaGen up 7% on foray into COVID-19

Thinly traded nano cap VistaGen Therapeutics ( OTC:VTGN +7.3% ) is up in early trade on double normal volume in reaction to its plan to expand development of PH94B, a rapid-onset neuroactive nasal spray, to include the potential treatment of adjustment disorder related to the stress of t...
Previous 10 Next 10